Cite
MLA Citation
Helena M Earl et al.. “6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.” Lancet, vol. 393, no. 10191, 2019, pp. 2599–2612. http://access.bl.uk/ark:/81055/vdc_100086506722.0x000048